Body mass index influences the response to infliximab in ankylosing spondylitis

Table 3 Response criteria influenced by BMI identified through multivariate analysis: a higher BMI is independently associated with a nonresponse of ankylosing spondyloarthritis to infliximab at month 6^a

^aAdjusted on significant factors in univariate analysis (P < 0.20). BASDAI, Bath ankylosing spondylitis disease activity index; CRP, C-reactive protein; NSAIDs, nonsteroidal antiinflammatory drugs; VAS, visual analogue scale.

ISSN: 1478-6362